BCG
DNLI icon

Breakwater Capital Group’s Denali Therapeutics DNLI Stock Holding History

Breakwater Capital Group’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$318K Sell
15,399
-202
-1% -$4.73K 0.04% 311
2026
Q2 		$401K Buy
15,601
+15
+0.1% +$308 0.05% 272
2026
Q1 		$299K Sell
15,586
-780
-5% -$15.5K 0.04% 306
2025
Q4 		$270K Buy
16,366
+500
+3% +$8.44K 0.04% 302
2025
Q3 		$230K Sell
15,866
-1,230
-7% -$17.7K 0.03% 324
2025
Q2 		$239K Buy
17,096
+2,081
+14% +$29.3K 0.04% 311
2025
Q1 		$204K Buy
+15,015
New +$288K 0.04% 320
2024
Q4 		– Sell
-7,642
Closed -$223K – 289
2024
Q3 		$223K Buy
+7,642
New +$189K 0.04% 269

Other funds holding DNLI

GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

Breakwater Capital Group's DNLI Position: Q3 2026 in Review

Breakwater Capital Group reduced its Denali Therapeutics (DNLI) stake by 1.3% in Q3 2026, selling an estimated $4.73K and leaving 15,399 shares worth $318K. The position accounts for 0.04% of the portfolio, ranked #311.

Breakwater Capital Group first reported a position in DNLI in Q3 2024 and has held it in 8 quarters since. The position peaked at $401K in Q2 2026. 5 funds tracked by Wall St. Rank hold DNLI as of Q3 2026.

  • Breakwater Capital Group held 15,399 shares of Denali Therapeutics worth $318K as of Q3 2026.
  • Breakwater Capital Group sold 202 Denali Therapeutics shares in Q3 2026, an estimated $4.73K.
  • Denali Therapeutics made up 0.04% of Breakwater Capital Group's portfolio in Q3 2026, its #311 holding.
  • Breakwater Capital Group first reported a position in Denali Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • Breakwater Capital Group's Denali Therapeutics position peaked at $401K in Q2 2026.
  • 5 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2026.

Based on Breakwater Capital Group's 13F filing for Q3 2026, filed 9 Oct 2026.